Bioxytran, Inc. Reports Promising ProLectin-M Study Results

BioXyTran, Inc., a biotechnology firm, disclosed results from its Phase 1b/2a clinical trial for ProLectin-M aimed at treating mild to moderate COVID-19. The study indicated that patients receiving the highest dose of 16,800 mg/day exhibited significantly faster viral clearance and clinical improvement by Day 5, compared to those on placebo. The trial, which involved 39 participants in India, revealed no serious adverse events.

The study's design utilized a randomized, double-blind, placebo-controlled framework, testing three dose levels alongside standard care. By Day 7, all patients showed viral clearance. The results suggest ProLectin-M may accelerate viral resolution, potentially filling treatment gaps in early respiratory infections. BioXyTran aims to advance ProLectin-M for further evaluation.

ProLectin-M targets galectins, proteins used by viruses for cellular entry. This unique approach promises broader antiviral application. The company positions ProLectin-M as a promising oral treatment avenue.